So different serological markers that contribute individually to prognosis of CLL such as β2-m and VEGF, integrating different clinical and biological aspects of CLL, provide prognostic information superior to those of a single marker. This evidence concerns the gene B2M and B-cell chronic lymphocytic leukemia.